Phase 2 Study of ONC201 in Neuroendocrine Tumors
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2017
At a glance
- Drugs ONC 201 (Primary)
- Indications Neuroendocrine tumours; Paraganglioma; Pheochromocytoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 09 Aug 2017 According to an Oncoceutics media release,the first patient has been treated in this trial at the Cleveland Clinic.
- 26 Jul 2017 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
- 26 Jul 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.